<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/18/volitionrx-nyseamericanvnrx-rating-reiterated-by-maxim-group.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-18T11:52:52+00:00"/>
    <meta property="og:title" content="VolitionRX (NYSEAMERICAN:VNRX) Rating Reiterated by Maxim Group"/>
    <meta property="og:description" content="Maxim Group reiterated their buy rating on shares of VolitionRX (NYSEAMERICAN:VNRX) in a research report report published on Thursday, AnalystRatings.com reports. Maxim Group currently has a $8.00 target price on the medical research company’s stock. VolitionRX stock traded down $0.15 during mid-day trading on Thursday, hitting $5.34. The company had a trading volume of 1,438 […]"/>
  </head>
  <body>
    <article>
      <h1>VolitionRX (NYSEAMERICAN:VNRX) Rating Reiterated by Maxim Group</h1>
      <address><time datetime="2019-11-18T11:52:52+00:00">18 Nov 2019, 11:52</time> by <a rel="author" href="https://www.thecerbatgem.com/author/teresa" target="_blank">Teresa Graham</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/volitionrx-ltd-logo.png"/>
      </figure>
      <p>Maxim Group reiterated their buy rating on shares of VolitionRX (NYSEAMERICAN:VNRX) in a research report report published on Thursday, <a href="https://www.analystratings.com/articles/maxim-group-maintains-a-buy-rating-on-volitionrx-vnrx//">AnalystRatings.com</a> reports. Maxim Group currently has a $8.00 target price on the medical research company’s stock.</p>
      <p><a href="https://www.marketbeat.com/stocks/NYSEAMERICAN/VNRX/price-target/">VolitionRX stock</a> traded down $0.15 during mid-day trading on Thursday, hitting $5.34. The company had a trading volume of 1,438 shares, compared to its average volume of 136,330. VolitionRX has a 1 year low of $1.67 and a 1 year high of $6.84.</p>
      <p>VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.06 million.</p>
      <p>In other VolitionRX news, major shareholder Corp Ltd Eight bought 50,000 shares of the stock in a transaction dated Tuesday, October 1st. The shares were acquired at an average cost of $5.95 per share, for a total transaction of $297,500.00. Also, Director Martin Charles Faulkes bought 10,000 shares of the stock in a transaction dated Tuesday, August 27th. The shares were acquired at an average price of $3.75 per share, for a total transaction of $37,500.00. The disclosure for this purchase can be found <a href="https://www.sec.gov/Archives/edgar/data/93314/000107878219000687/primary_doc.xml">here</a>.</p>
      <p>An institutional investor recently raised its position in VolitionRX stock. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of VolitionRX Ltd (NYSEAMERICAN:VNRX) by 44.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,500 shares of the medical research company’s stock after acquiring an additional 10,000 shares during the period. Ladenburg Thalmann Financial Services Inc. owned 0.08% of VolitionRX worth $102,000 at the end of the most recent reporting period.</p>
      <p>
        <b>VolitionRX Company Profile</b>
      </p>
      <p>VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.</p>
      <p>Further Reading: <a href="https://www.marketbeat.com/financial-terms/what-is-qqq-etf/">QQQ ETF</a></p>
    </article>
  </body>
</html>